Nectar Lifesciences Limited, a pharmaceutical company, primarily engages in the development, manufacture, and marketing of various active pharmaceutical ingredients (APIs) and finished dosage forms. The company's APIs and intermediates include cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCL, cefepime HCL, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company's finished dosage forms consist of tablets, capsules, dry powder oral suspension, and granules and injectibles. Nectar Lifesciences also offers contract research and manufacturing services, such as process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, pilot plant production, bulk production, and Chiral resolution, as well as provides chemical and analytical development services. In addition, the company offers generic and OTC products, empty hard gelatin capsules, and diagnostics products; and manufactures menthol and allied products, including menthol crystals, menthol flakes, peppermint oil, mentha piperita, Indian spearmint oil, menthones, mint blends, dementholised peppermint oil, and mint based products. Nectar Lifesciences Limited was incorporated in 1995 and has its office based in Delhi.
Headquarters
A-920, 9th Floor,, Naurang House, 21 K G Marg
Delhi; Delhi;
Postal Code: 110001
Contact Details: Purchase the Nectar Lifesciences Ltd. report to view the information.
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service